Axatilimab and ECP for chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a donor (allogeneic).
- You are 12 years or older.
- You have chronic graft-versus-host disease (cGVHD) that hasn't improved after at least 2 prior treatments or that needs high steroid doses.
- You are not currently pregnant or breastfeeding.
- You do not have active cancer, serious infections, or certain lung or bleeding problems.
- You have stable IV access for the blood treatment (central line, PICC, or good vein).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
This trial tests an experimental drug called adrixetinib (Q702) for people with active chronic graft-versus-host disease that has not responded well to standard treatments. It aims to see if the drug can help control your symptoms when other options have stopped working.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.